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1. Introduction 
Neoadjuvant systemic therapy (NST) has become a frequently used option for systemic 
therapy in primary operable breast cancer. All patients with a clear indication for adjuvant 
systemic treatment can be offered systemic therapy preoperatively. These recommendations 
focus on early response to NST and on tailoring therapy to response and biological and 
histological markers. 
Three main goals for NST in operable breast cancer were defined: 
- To reduce mortality from breast cancer with reduced toxicity. 
- To improve surgical options. 
- To acquire early information on response and biology of the disease. 
A recent Oxford meta-analysis (EBCTCG, 2005) of randomized studies of more than 4000 
women, comparing postoperative and neoadjuvant chemotherapy for operable breast 
cancer, demonstrated equivalent overall survival rates with a hazard ratio of 0.98 (p = 0.67). 
Neoadjuvant chemotherapy was associated with fewer adverse effects, and associated with 
a higher rate of breast conserving surgery (p < 0.001). In addition, patients who achieved a 
pCR had a better survival than those who had residual disease in the breast and lymph 
nodes. Neoadjuvant chemotherapy is associated with a small increase in the risk of loco-
regional recurrence in patients who went on to receive radiotherapy without surgery as 
local therapy. 
2. Neoadjuvant systemic therapy 
2.1 Neoadjuvant chemotherapy 
Some early nonrandomized and randomized trials suggested that neoadjuvant 
chemotherapy might result in improved disease-free survival rates compared with standard 
adjuvant treatment (Scholl et al., 1994; Semiglazov et al. 1994), but some of these trials were 
not designed as a direct comparison of preoperative and postoperative chemotherapy. In 
1998, the National Surgical Adjuvant Breast and Bowel Project (NSABP) reported the result 
of a large prospective randomized trial (Protocol B- 18) that compared 4 cycles of 
doxorubicin and cyclophosphamide (AC) given preoperatively to the same dose of AC 
given postoperatively (Fisher et al., 1998; Wolmark et al., 2001). The disease-free survival 
and overall survival rates for the 2 treatment arms of this trial were almost identical. B-18 
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demonstrated that clinical and pathologic tumor response were predictors of overall 
survival. Similar to other reports, despite a 36% clinically complete response (cCR) rate, only 
13% of all patients had a pathologically complete response (pCR), defined as the absence of 
invasive tumor in the breast. A meta-analysis of 9 randomized studies (not involving 
taxanes) demonstrated the equivalence of neoadjuvant and adjuvant treatments for breast 
cancer in terms of survival, disease progression, and distant recurrence and showed that an 
increased risk of locoregional disease recurrence is associated with neoadjuvant treatment, 
especially when primary systemic treatment is not accompanied by any surgical 
intervention (eg, radiation therapy alone) (Mauri et al., 2005). 
Preoperative neoadjuvant chemotherapy with agents such as doxorubicin and taxanes is an 
effective treatment for patients with breast cancer and leads to an increased rate of successful 
breast- conserving surgery and a decreased proportion of patients with metastatic 
involvement of the axillary lymph nodes (Kaufmann et al., 2006). Neoadjuvant chemotherapy 
also provides an opportunity to assess potential responses of the tumor to a given agent, 
which is an important consideration in selecting postoperative (adjuvant) therapy. Data from 
large phase 2 and phase 3 chemotherapy trials have shown that 3 to 4 months of 
preoperative treatment can be given without compromising either locoregional control or 
long-term survival (Bonadonna et al., 1998; Smith et al., 2002). 
The NSABP Protocol B-27 was designed to determine the effect of adding docetaxel after 4 
cycles of preoperative doxorubicin and cyclophosphamide on clinical and pathological 
response rates and on disease-free survival and overall survival of women with operable 
breast cancer. There were trends toward improved disease-free survival with the addition of 
docetaxel. Preoperative docetaxel, but not postoperative docetaxel, significantly improved 
disease-free survival in patients who had a clinical partial response after doxorubicin and 
cyclophosphamide. Pathologic complete response, which was doubled (from 13% to 26%) 
with preoperative docetaxel, was a significant predictor of overall survival regardless of 
treatment (Bear et al., 2006). 
European Cooperative Trial in Operable Breast Cancer (ECTO) was designed to assess the 
effects of adding paclitaxel to an anthracycline- based regimen in patients with operable 
breast cancer, and to compare the same regimen given preoperatively and postoperatively 
(Gianni et al., 2009). 
The ECTO study found a significant improvement in distant recurrence free survival (DRFS) 
in patients with operable early-stage breast cancer when paclitaxel was incorporated into a 
sequential adjuvant regimen of noncross-resistant chemotherapies that was originally 
pioneered by the Milan group (Gianni et al., 2009). This advantage was also seen in women 
with node-negative disease who constituted 40% of patients enrolled in the adjuvant arms. 
Comparison of the same paditaxel/doxorubicin/CMF regimen given preoperatively instead 
of postoperatively resulted in similar DRFS but a significantly higher percentage of patients 
were able to undergo breast-conserving surgery without a detrimental effect on local 
recurrence or survival. 
The ECTO study recruited a typical and representative sample of patients and its findings 
are consistent with a recent meta-analysis from the Early Breast Cancer Trialists Group, 
which showed that taxane-based adjuvant regimens are superior to anthracycline-based 
regimens in terms of recurrence rate (Peto, 2007). Pooled data from another meta-analysis 
also showed that incorporation of taxanes into anthracycline-based regimens significantly 
improved both disease-free (DFS) and overall survival (OS) in patients with early-stage 
breast cancer (De Laurentiis et al., 2008). 
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2.2 Duration and sequence of neoadjuvant chemotherapy 
The superior outcomes of patients who achieved favorable responses in the breast had led 
investigators to question whether using in-breast response as an in vivo chemosensitivity test 
and tailoring therapy accordingly may improve outcomes. GeparTrio was one of the studies 
that set out to answer this question. In this multicenter German study, all 2,090 patients 
received an initial 2 cycles of neoadjuvant TAC chemotherapy (docetaxel 75 mg/m2, 
doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2 every 21 days). Patients were 
then divided on the basis of sonographic evaluation into responders (tumor size decreased 
by > 50%) and nonresponders (tumor size decreased by < 50%). A third group, patients 
whose tumors increased in size by 25% or more, was removed from the study and treated at 
the discretion of their oncologist. The study continued in two parts, one evaluating a change 
of therapy for nonresponders, and one evaluating the optimal duration of therapy in the 
responders (Von Minckwitz et al., 2008). 
In the first part, the 622 patients who did not respond to the initial 2 cycles of TAC 
chemotherapy were randomly assigned to four more cycles of TAC chemotherapy or four 
21-day cycles of an NX regimen (vinorelbine 25 mg/m2 on days 1 and 8 and capecitabine 
[Xeloda] 1,000 mg/m2 orally twice daily on days 1-14). Sonographic response rate was 
chosen as the primary endpoint, and it should be noted that the statistical plan was based 
on a hypothesis of non-inferiority (rather than superiority) of NX compared to TAC. There 
was no difference in sonographic response rates for the two regimens, confirming the 
non-inferiority of NX. The rates of pCR were low for both NX and TAC, at 6.0% and 5.3%, 
respectively. It must be emphasized that this study did not set out to demonstrate an 
improvement in outcome for switching to a non- cross-resistant chemotherapy regimen, 
nor did it show such a difference. In the second part of the GeparTrio study, the 1,390 
patients who responded to an initial 2 cycles of neoadjuvant TAC chemotherapy were 
randomized to either 4 or 6 further cycles of TAC pre-operatively, ie, 6 versus 8 cycles in 
total. The primary aim of this part of the study was to detect an increased pCR rate of 26% 
versus 20% in the I group receiving a longer duration of therapy. There were no 
significant differences in the rates of pCR (8 cycles 23.5% vs 6 cycles 21.0%, P = 0.27) or 
BCS (67.5% vs 68.5%, P = .68) (von Minckwitz et al., 2008). Thus, the knowledge of 
chemotherapy sensitivity does not appear to predict a greater benefit for more of what 
was already proven effective (TAC, in this case). 
The Aberdeen study also assessed the potential benefit of switching chemotherapy regimens 
in the neoadjuvant setting, but in this case the randomization between "sticking or 
switching" occurred in the responders rather than the nonresponders (Smith et al., 2002). In 
this study, 162 patients were enrolled and received four 21-day cycles of an anthracycline 
chemotherapy regimen (CVAP: cyclophosphamide 1,000 mg/m2, vincristine 1.5 mg/m2, 
doxorubicin 50 mg/m2, and prednisolone 40 mg for 5 days). The 104 patients classified as 
responders by clinical assessment were randomized to 4 cycles of CVAP or 4 cycles of 
docetaxel (100 mg/m2 every 21 days). All 55 nonresponders received 4 cycles of docetaxel. 
Intention-to-treat (ITT) analysis showed that the addition of docetaxel significantly 
enhanced cRR in the responders, compared to continuation of CVAP (85% vs 64%, P =0 .03). 
The pCR rate was also superior in the docetaxel group (ITT analysis, 31% vs 15%, P =0 .06; 
for patients completing 8 cycles, 34% vs 16%, P =0.04). In addition, updated follow-up at 3 
years indicated improved survival in the docetaxel arm, although this was not a primary 
endpoint of the study design and was not incorporated into statistical plan (Heys et al., 
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2002). However, nonresponders also benefited from switching to docetaxel, with over half 
(55%) of these patients going on to achieve clinical responses, and a small proportion (2%) 
achieving pCRs. Neither the GeparTrio nor the Aberdeen studies therefore provide evidence 
of a convincing role for response (or lack thereof) to neoadjuvant chemotherapy as an in vivo 
tool for chemotherapy selection, but they suggest that most patients may benefit from 
exposure to a varied chemotherapy approach in the neoadjuvant setting. 
2.3 Neoadjuvant endocrine therapy 
A useful strategy to improve knowledge about treatment effects is the early identification of 
features, which are associated with response or resistance to primary therapy. Previously 
published studies indicated that pathological complete remission (pCR) rate was significantly 
higher following preoperative chemotherapy for patients whose tumors did not express 
estrogen receptor (ER) and progesterone receptor (PgR), compared with the receptor- positive 
cohort (Ring et al., 2004; Colleoni et al., 2004). Despite the significantly higher incidence of pCR 
achieved by preoperative chemotherapy for patients with endocrine-nonresponsive disease, 
the disease-free survival (DFS) was significantly worse for this cohort compared with the ER 
positive expression cohort in several studies (Colleoni et al., 2008). 
More recently neoadjuvant endocrine therapy has emerged as an attractive alternative in 
postmenopausal women with large or inoperable hormone receptor positive breast cancers. 
Although there have been no large randomized trials comparing surgery with neoadjuvant 
endocrine therapy, there have been a series of studies using aromatase inhibitors (AIs) 
which have produced promising results. A number of large randomized trials have 
compared various AIs directly with tamoxifen. An important endpoint in each of these 
studies has been the rate at which breast conservation has been achieved. There are a 
number of benefits to using neoadjuvant therapy compared with primary surgery. The most 
obvious benefit is that women with large operable or locally advanced breast cancers can be 
downstaged allowing them to become operable or more suitable for less extensive surgery 
(Dixon & Macaskill, 2009). For instance, those who originally would have required 
mastectomy can often be converted to breast-conserving surgery. This is an advantage 
because studies have demonstrated that breast-conserving surgery followed by 
radiotherapy has significant psychological benefits, better cosmetic outcomes, and 
comparable disease control rates compared to mastectomy. There are as yet limited long-
term data on patients who have had breast-conserving surgery after neoadjuvant therapy, 
but the results to date are reassuring. The majority of patients who are spared mastectomy 
with neoadjuvant endocrine therapy are elderly, but studies have shown that even in older 
women, if they are given the choice, they are no more likely to choose mastectomy than 
younger women. Neoadjuvant endocrine therapy is also an excellent treatment for older 
patients with estrogen receptor cancers who are unfit for surgery because of significant 
comorbidities. For these patients, shrinkage can allow resection under local anesthesia, or 
for a select group with short life expectancy, treatment with endocrine therapy can provide 
long-term disease control for the rest of their lives. 
2.3.1 Letrozole compared with tamoxifen 
The first endocrine neoadjuvant study was the P024 trial and included 337 postmenopausal 
women with large operable or locally advanced ER-positive and PR-positive breast cancers 
(Eiermann et al., 2001). All patients required mastectomy at diagnosis or were inoperable. In 
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this study patients were randomly selected to receive 4 months of letrozole or 4 months of 
tamoxifen. Objective response rates (ORR) by palpation, mammography, and ultrasound 
were all significantly higher in the letrozole treated group. There was also a significantly 
higher rate of breast-conserving surgery for patients randomly assigned to receive letrozole 
(45% vs. 35% in the tamoxifen group; p = 0.022). 
2.3.2 Anastrozole compared with tamoxifen 
Two large randomized studies have compared anastrozole with tamoxifen. In the 
Immediate Preoperative Arimidex, Tamoxifen or Combined with Tamoxifen (IMPACT) 
trial, 330 patients from the UK and Germany were randomly selected to receive anastrozole 
alone, tamoxifen alone, or a combination for 3 months before surgery (Smith et al., 2005). 
The study differed from P024 in that patients who were suitable for breast-conserving 
surgery at the outset were enrolled. There was no significant difference seen in ORRs 
between the three treatments as measured by calipers and ultrasound. There was a 
subgroup of 124 patients who were considered to require mastectomy at baseline. Although 
there remained no difference in this group in ORR, a significantly higher number of women 
were deemed suitable for breast-conserving surgery following treatment with anastrozole, 
compared with tamoxifen (46% vs. 22%; p = 0.03). 
In the Preoperative Arimidex Compared with Tamoxifen trial, the entry criteria was similar 
to the IMPACT trial, although this study also included patients who were inoperable 
(Cataliotti et al., 2006). This study also differed in that it included a group of patients who 
were given concurrent neoadjuvant chemotherapy. Randomisation was to the 202 patients 
treated with anastrozole alone or the 201 patients treated with tamoxifen alone for 3 months. 
There was no significant difference in ORR by ultrasound or caliper measurements between 
the different treatment arms, although there was a trend in favor of anastrozole for those 
patients treated with neoadjuvant endocrine therapy alone. There was a significantly higher 
ORR in the anastrozole group for patients whose tumors were initially assessed as requiring 
mastectomy or were inoperable. 
A combined analysis of the two anastrozole studies included 535 patients and again failed to 
show any difference between treatments (Smith, 2004). There was again an overall 
improvement in ORR in favor of anastrozole in the subgroup of patients who were deemed 
to require mastectomy or be inoperable at the outset. Both were assessed by calipers (47% 
vs. 35%; p = 0,026) and ultrasound (36% vs. 26%; p = 0.048). A significant change in both 
feasible and actual surgery in favor of anastrozole was also evident for those patients who 
required a mastectomy or were inoperable at diagnosis. 
2.3.3 Exemestane compared with tamoxifen 
Several recent studies support the use of aromatase inhibitors as neoadjuvant therapy for 
hormone-responsive breast cancer. For example, we reported the results of a study 
comparing the efficacy of exemestane and tamoxifen as neoadjuvant therapy (Semiglazov et 
al., 2005). In that study, 151 postmenopausal women with ER-positive and/or PgR-positive 
breast cancer were randomly assigned to receive exemestane or tamoxifen for 3 months. 
Neoadjuvant treatment with exemestane significantly improved clinical objective response 
(76% vs 40%; P = .05) and the rate of breast-conserving surgery (37% vs 20%; P =0.05), but it 
did not result in any significant differences in objective response as determined by 
mammogram or ultrasound. Thus, exemestane is more effective than tamoxifen as a 
neoadjuvant treatment option for postmenopausal women with ER-positive disease. 
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2.3.4 Hormonal versus chemotherapy in the neoadjuvant treatment 
Duration of neoadjuvant hormonal treatment for breast cancer in most studies was 3-6 
months. The few studies that investigated prolonged treatment with neoadjuvant endocrine 
therapy suggest that a further reduction in tumour size can be achieved and that even 
surgery can be withheld for elderly women on continuing hormonal treatment. However, 
the optimum duration of neoadjuvant endocrine therapy has to be established. 
For many years, primary systemic (neoadjuvant) therapy has been given before local 
treatment for women with locally advanced breast cancer in an effort to make such disease 
operable. Chemotherapy has been the mainstay of this approach, but more recently 
neoadjuvant endocrine therapy has emerged as an attractive alternative in post-menopausal 
women with large hormone receptor positive breast cancers. A number of randomized trials 
(like P024, IMPACT, PROACT) have compared various aromatase inhibitors directly with 
tamoxifen. An important endpoint in each of these studies has been the rate at which breast 
conservation has been achieved. The presence of steroid hormone receptors (ER and/or PR) 
are target for endocrine therapy. Preoperative chemotherapy may be less effective in 
postmenopausal patients with ER-positive and/or PR-positive tumors at least with respect 
to doxorubicin-containing or taxane-containing regimens. Pathological complete response 
(pCR) rates after chemotherapy were significantly higher among patients with tumors that 
were both ER-negative and PR-negative compared with patients whose tumors had any 
(even low) expression of steroid hormone receptors (Colleoni et al. 2004, 2008). In the ECTO 
I trial, pCR after neoadjuvant chemotherapy was observed in 42% of women with ER-
negative tumors, compared with 12% in the ER-positive group (Gianni et al. 2009). In the 
NSABP B-27 study, ER-negative tumors had higher rates of pCR than ER-positive tumors 
when treated with neoadjuvant AC, as well as when treated with AC followed by docetaxel 
(Bear ., et al. 2006). Before our trial there were few, if any, direct comparisons of primary 
neoadjuvant endocrine therapy with primary neoadjuvant chemotherapy in patients with 
hormone-responsive breast cancer. 
This was an open-label, randomized phase 2 trial of once-daily endocrine therapy 
(exemestane or anastrozole) or chemotherapy (doxorubicin and paclitaxel, every 3 week for 
4 cycles) in postmenopausal women with primary ER-positive breast cancer. A total of 239 
patients with ER-positive and/or PgR-positive breast cancer (T2N1-2, T3N0-1, T4N0M0) 
were randomly assigned to receive neoadjuvant endocrine therapy (ET) [anastrazole 1 
mg/day or exemestane 25 mg/day for 3 months, 121 patients] or chemotherapy (CT) 
[doxorubicin 60 mg/m2 with paclitaxel 200 mg/m2, four 3-week cycles, 118 patients]. All 
patients were considered to be ineligible for breast-conserving surgery (BCS) at enrollment. 
After BCS all patients received radiotherapy (50 Gy in 25 fractions). The median follow-up 
time was 5.6 years. 
The primary efficacy end point was already reported (Semiglazov et al., 2007). Overall 
response (OR=CR+PR) was similar in the endocrine therapy group (65.5%) compared with 
chemotherapy group (63.6%; p>0.5). 
Interim analysis of this trial showed similar objective response in patients who were 
receiving exemestane and in patients who were receiving anastrazole. It allowed us to 
review and to analyze dates on all patients who were receiving aromatase inhibitors in the 
endocrine therapy group. 
There was a trend toward higher overall rates of OR and breast-conserving surgery among 
patients with tumors expressing high levels of ER (Allred score ≥6) in the endocrine therapy 
compared with the chemotherapy group (43% vs 24%, p=0.054; Table 1). 
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 Endocrine 
Therapy 
Chemotheapy  
Response, n (%) (n=70) (n=63) P Value 
Clinical objective response 49 (70) 38(60) 0.068 
Mammography 46 (66) 38 (60) 0.088 
Breast-conserving surgery 30(43) 15 (24) 0.054 
*High levels of estrogen receptor expression are defined as ≥6 Allred score or ≥120 fmol/g.  
Table 1. Overall Objective Response in Patients With High Levels of Estrogen Receptor 
Expression* 
After completing neoadjuvant treatment, 31 patients (13%) did not undergo surgical 
resection: 12.3% of patients who were receiving endocrine therapy and 13.5% of patients 
who were receiving chemotherapy. Twenty-two patients did not receive surgery because of 
disease progression. These patients were switched to the other study therapy: patients 
initially treated with endocrine therapy received chemotherapy, and patients treated with 
chemotherapy received endocrine therapy. Progressive disease was observed in 9% of 
patients who were receiving endocrine therapy and 9% of patients who were receiving 
chemotherapy (P>0.5). Stable disease was seen in 21% of patients who were receiving 
endocrine treatment and 26% of patients who were receiving chemotherapy. 
Analysis of BCS rates according to pretreatment characteristics showed a non-significant 
trend towards increased BCS in patients with clinical stage T2, ER+/PgR+, 70 years and 
older (p=0.054- 0.088) receiving neoadjuvant endocrine therapy. 
The rate of BCS was particularly marked in patients receiving endocrine therapy, who 
achieved a clinical response. There was no significant difference between endocrine therapy 
(ET) and chemotherapy (CT) relative to the incidence of locoregional recurrences and distant 
metastases (8.2% and 7.6%, p=0.99; 14.8% and 15.2%, p=0.83, respectively). There was no 
significant difference in DFS through 5 years of follow up between the 121 patients who 
received neoadjuvant endocrine therapy and 118 women who received chemotherapy: 
71.0% and 67.7% (p>0.5). After a median follow up of 5.6 years 35 events had been reported 
in the endocrine group (24 in 66 patients who underwent mastectomy and 11 in 40 patients 
who underwent BCS). 5-year DFS was 63.6% after mastectomy and 72.5% after BCS 
(p=0.076). The incidence of commonly reported adverse events was higher in patients 
receiving chemotherapy. No serious adverse events were reported in patients receiving 
endocrine therapy. Six patients receiving chemotherapy experienced febrile neutropenia 
leading to treatment interruption. No deaths occurred during the preoperative therapy. 
Our trial has shown that preoperartive endocrine therapy with aromatase inhibitors offers 
the same rate of overall objective response, breast-conserving surgery, 5-years DFS as 
chemotherapy in postmenopausal patients with ER-positive tumors. The frequency of 
adverse events was higher among patients who were receiving chemotherapy. Endocrine 
treatment was well tolerated. Preoperative endocrine therapy with aromatase inhibitors is a 
reasonable alternative to preoperative chemotherapy for postmenopausal women with ER-
positive disease in clinical situation in which the low toxicity of the regimen is considered an 
advantage. According St.Gallen recommendation (Goldhirsch et al., 2009) neoadjuvant 
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endocrine therapy without chemotherapy was considered reasonable for postmenopausal 
patients with strongly receptor-positive disease. If used, such treatment should be 
considered for a duration of 5-8 months or until maximum tumour response. 
2.4 Neoadjuvant therapy in HER2+ breast cancer 
Amplification or overexpression, or both, of human epidermal growth factor receptor-2 
(HER2, also known as ERBB2), a transmembrane receptor tyrosine kinase, is present in around 
22% of early breast cancers, 35% of locally advanced and metastatic tumours, and 40% of 
inflammatory breast cancers, and is associated with aggressive disease and poor prognosis 
(Ross et al., 2009). Patients with HER2-positive locally advanced or inflammatory breast cancer 
are therefore in particular need of effective treatment. Trastuzumab (Herceptin, Roche, Basel, 
Switzerland), a recombinant humanized monoclonal antibody that targets HER2, has efficacy 
as monotherapy (Baselga et al., 2005) and improves results of chemotherapy in patients with 
HER2-positive metastatic (Slamon et al., 2001; Marty et al., 2005) and early operable breast 
cancer (Smith et al., 2007; Romond et al., 2005; Slamon et al., 2005). It is widely approved for 
use as monotherapy and in combination with chemotherapy or hormone therapy in these 
patients, but not specifically in those with locally advanced or inflammatory breast cancer. In a 
pilot study, anthracycline and paclitaxel were successfully combined with trastuzumab in 
patients with metastastic disease (Bianchi et al., 2003). To reduce the risk of cardiac toxic 
effects, only three cycles of doxorubicin were given in the pilot study, which corresponds to a 
cumulative dose of 180 mg per m2 of body surface area (Gianni et al., 2009). No patient 
developed symptomatic cardiac dysfunction, although four patients (of 16) had reversible 
asymptomatic decreases in left ventricular ejection fraction to 50% or lower. 
The neoadjuvant Herceptin (NOAH) study was designed to assess efficacy of neoadjuvant 
chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant 
chemotherapy alone in patients with HER2-positive locally advanced or inflammatory 
breast cancer. The NOAH study randomized 228 patients with centrally confirmed HER2+ 
locally advanced breast cancer to a chemotherapy regimen consisting of 3 cycles of 
doxorubicin plus paclitaxel (AT); 4 cycles of paclitaxel (T); and 3 cycles of 
cyclophosphamide, methotrexate, and fluorouracil (CMF), with and without trastuzumab. 
The addition of trastuzumab significantly improved overall response rate (81% vs 73%, P =0. 
18) and pCR rates (43% vs 23%, P =0 ,002) (Gianni et al., 2010).  
The primary objective was to compare event-free survival, which was defined as time 
from randomization to disease recurrence or progression (local, regional, distant, or 
contralateral) or death from any cause, in patients with HER2-positive disease treated 
with and without trastuzumab. 
Trastuzumab significantly improved event-free survival in patients with HER2-positive breast 
cancer (3-year event-free survival 71% [95% CI 61-78; n=36 events] with trastuzumab, vs 56% 
[46-65; n-51 events] without; hazard ratio 0.59 [95% CI 0-38-0-90]; p-0.013). Trastuzumab was 
well tolerated and, despite concurrent administration with doxorubicin, only two patients (2%) 
developed symptomatic cardiac failure. Both responded to cardiac drugs. 
The results of the NOAH study have shown that in patients with HER2-positive locally 
advanced or inflammatory breast cancer, addition of 1 year of trastuzumab (starting as 
neoadjuvant and continuing as adjuvant therapy) to neoadjuvant chemotherapy improved 
overall response rates, almost doubled rates of pathological complete response, and reduced 
risk of relapse, progression, or death compared with patients who did not receive 
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trastuzumab. Investigators recorded a benefit of trastuzumab in all subgroups tested, 
including women with inflammatory disease (27% of HER2- positive patients) who 
benefited substantially from trastuzumab. 
The results of the NOAH study consolidate those of other studies of trastuzumab in the 
neoadjuvant setting. In these mainly non-randomised studies, pathological complete 
response rates (variously defined) ranged from 17% to 73%, and were better than they were 
in historical' or concurrent HER2-negative controls (Gluck et al., 2008; Untch et al., 2008). 
One randomised trial in patients with operable non-inflammatory disease was stopped early 
when the pathological complete response rate in the trastuzumab group was more than 
twice as high as that of the control group (65% vs 26%) (Buzdar et al., 2005). Patient numbers 
in this study were small, but preliminary results from another randomized study also show 
a doubling in pathological complete response rate in the trastuzumab group. These response 
rates to primary systemic therapy are a surrogate for relapse-free and overall survival in 
patients who were unselected for HER2 status.  
Despite concurrent use of doxorubicin, paclitaxel, and trastuzumab in the NOAH trial, 
incidence of symptomatic cardiac failure was low (<2%) and less than was expected (2.8-
4.1%) on the basis of adjuvant trials in which trastuzumab was given concurrently with 
paclitaxel after completion of doxorubicin and when trastuzumab was given as 
monotherapy after completion of a range of cytotoxic regimens (2%). These findings 
support the accumulating evidence that trastuzumab can be given concurrently with 
anthracyclines with a low frequency of symptomatic cardiac dysfunction, provided that 
low cumulative doses or less cardiotoxic anthracyclines are used, and careful cardiac 
monitoring is done. 
The addition of trastuzumab to neoadjuvant sequential anthracycline-taxane chemotherapy 
(with and without capecitabine) was also investigated in the phase III GeparQuattro study, 
and led to a doubling of pCR rates (31.8% vs 15.4%, P <0.001) (Von Minckwitz et al., 2008). 
With the emergence of lapatinib (Tykerb), a dual tyrosine kinase inhibitor against HER1 and 
HER2, the CALGB is conducting a randomized phase III trial to evaluate paclitaxel with 
trastuzumab or lapatinib, or both in the preoperative setting. Several other trials are 
ongoing to evaluate these 2 drugs in the neoadjuvant setting, including Neo-ALTTO 
(Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization) in phase III and 
CHERLOB in phase II. 
Trastuzumab (H) in combination with chemotherapy improves outcomes in patients with 
HER2-positive breast cancer and is integral to the standards of care for these patients. 
However, in some patients disease progression still occurs. Pertuzumab (P) and trastuzumab 
(H) target different epitopes of HER2, and their use in combination has demonstrated 
improvement in response rates. NEOSPHERE study (Gianni et al., 2011) assessed the efficacy 
and safety of pertuzumab added to trastuzumab-based neoadjuvant chemotherapy in 
women with HER2-positive operable, locally advanced/inflammatory breast cancer who 
had not received prior cancer therapy. 
Patients (n = 417) with HER2-positive (IHC3+ or IHC2+ and FISH/CISH+) breast cancer 
were randomized 1:1:1:1 to receive 4 neoadjuvant cycles of docetaxel (T) plus H, THP, HP or 
TP. Pertuzumab (P) was given at a loading dose of 840 mg and 420 mg maintenance, 
trastuzumab (H) at a loading dose of 8mg/kg and 6 mg/kg maintenance, and docetaxel (T) 
at 75 mg/m2 with escalation to 100 mg/m2 if tolerated in a 3weekly schedule. The primary 
endpoint was pCR in the breast. 
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About 40% of patients had locally advanced/inflammatory breast cancer and approximately 
50% were ER/PR negative. THP combination (docetaxel + trastuzumab + pertuzumab) 
significantly improved the pCR rate compared with TH (docetaxel + trastuzumab) alone: 
45.8% (95% CI 36.1-55.7) vs 29.0% (95% CI 20.6-38.5), p = 0.0141. Patients receiving THP 
(docetaxel + trastuzumab + pertuzumab) had the highest pCR rate regardless of ER/PR 
status, although the greatest treatment benefit in all 4 arms was observed in ER/PR-neg 
patients. The chemotherapy-free HP (trastuzumab+pertuzumab) arm achieved a pCR rate of 
16.8%. THP (docetaxel + trastuzumab + pertuzumab) had a similar safety profile to TH. The 
incidence of AEs was lowest in the HP (trastuzumab+pertuzumab) arm. 
Thus, the addition of pertuzumab to trastuzumab-based neoadjuvant chemotherapy 
resulted in a significant improvement of the pCR rate with no new safety signals of concern. 
Pertuzumab and trastuzumab have complementary mechanisms of action as pertuzumab 
inhibits HER2:HER3 heterodimerisation, thereby providing a potential mechanism to 
overcome tumour escape. These results support the rationale for a planned Phase III, 
double-blind, placebo-controlled trial evaluating pertuzumab added to standard 
trastuzumab-based therapy in women with HER2- positive breast cancer. 
Despite the dramatic improvement in the outcome of HER2+ breast cancers since the 
widespread use of HER2-directed therapies, such as trastuzumab, patients continue to 
develop recurrences and disease progression. The mechanisms of intrinsic and acquired 
resistance to trastuzumab are likely multifactorial and are being exploited by the use of 
novel targeted agents in clinical development. The phosphoinositide-3-kinase (PI3K) 
pathway plays a key role in resistance to trastuzumab through increased signaling through 
upstream growth factor receptors, PTEN mutations, and other mechanisms, and therefore, is 
an excellent target for drug development in patients with trastuzumab-resistant, HER2+ 
breast cancers. Available clinical trials demonstrate encouraging activity of mTOR inhibitors 
in combination with trastuzumab monotherapy or trastuzumab-based chemotherapy in 
patients with HER2+ metastatic breast cancer pretreated with trastuzumab with or without 
lapatinib. The results of early-stage clinical trials are currently being confirmed in 2 large 
phase III trials (Brachman et al., 2009; Vazguez-Martin et al., 2009). Other agents, targeting 
the PI3K pathway, are in early clinical development for HER2+ breast cancers.  
Cross-talk between the estrogen receptor (ER) and the phosphoinositide-3-kinase 
(PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways is a mechanism of 
resistance to endocrine therapy, and blockade of both pathways enhances antitumor 
activity in preclinical models. Study of Baselga et al.(2009) explored whether sensitivity to 
letrozole was enhanced with the oral mTOR inhibitor, everolimus (RAD001). Response 
rate by clinical palpation in the everolimus arm was higher than that with letrozole alone 
(ie, placebo; 68.1% v 59.1%), which was statistically significant at the preplanned, one-
sided, α=0.1 level (P=0.062). Marked reduction in progesterone receptor and cyclin D1 
expression occurred in both treatment arms, and dramatic downregulation of phosphor-
S6 occurred only in the everolimus arm. An antiproliferative response, as defined by a 
reduction in Ki67 expression to natural logarithm of percentage positive Ki67 of less than 
1 at day 15, occurred in 52 (57%) of 91 patients in the everolimus arm and in 25 (30%) of 82 
patients in the placebo arm (P<0.01). 
The exact mechanism by which mTOR inhibitors appear to reverse resistance to 
trastuzumab remains unclear. Future clinical trials should attempt to delineate these 
mechanisms so that patients can be selected appropriately for these therapeutic approaches. 
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2.5 Triple-negative breast cancer 
Triple-negative (ER-negative, PgR-negative, and HER2 receptor-negative) breast cancers 
(TNBC) account for approximately 15% of all breast cancers and, though in and of itself it 
is a heterogeneous group, it often exhibits an aggressive phenotype with a generally poor 
prognosis. Unlike HER2+ or hormone receptor- positive breast cancers, triple-negative 
tumors lack an established therapeutic target and though initially responsive to many 
standard treatment regimens, progression and recurrence can be rapid and refractory to 
alternative approaches. Loss or inactivation of breast cancer type 1 (BRCA1) leads to 
defects in certain DNA repair pathways. Most BRCA1 mutant breast cancers lack ER, PgR, 
and HER2 expression, and this association has raised the question of defective BRCA1 
function in sporadic (non-familial) TNBC (Sorlie et al., 2003). This led to the hypothesis 
that triple-negative tumors may be more sensitive to DNA damaging agents, such as 
platinums. A retrospective analyses of patients with triple-negative breast cancer who 
received taxane/ platinum-based primary chemotherapy demonstrated an overall 
response of 39% (Uhm et al., 2009), while studies of platinum monotherapy or 
combinations in the neoadjuvant setting have produced pCR rates of 22%-50% (Garber et 
al., 2006; Chang et al., 2008). 
To exploit the defective DNA repair mechanisms in triple-negative and BRCA-deficient 
breast cancers, recent trials investigated the effect of interfering further with DNA repair 
through the use of novel small molecule inhibitors of poly-ADP ribose polymerase (PARP). 
This is a critical enzyme in cell proliferation and DNA repair. Results from several 
preliminary trials have been reported. The first was a phase II trial which evaluated the oral 
PARP inhibitor, olaparib, as a single agent as second- or later-line therapy in 54 patients 
with locally advanced or metastatic BRCA-deficient breast cancer (Tutt et al., 2009). Despite 
this use of olaparib as a single agent in a pretreated population, a response rate of4l% was 
reported for patients receiving the higher of 2 evaluated doses.  
One of the key issues related to interpretation of trials investigating triple-negative breast 
cancer is the heterogeneity of this tumor subtype. Although most basal-like tumors are 
also triple-negative, there is discordance between triple-negative designation on clinical 
assays and basal-like breast cancer on gene expression arrays (Schneider et al., 2008). 
There is also heterogeneity within triple-negative breast cancer regarding expression of 
p53, BRCA1, and other relevant genes. Thus, there is danger in making clinical decisions 
based on cross- trial comparisons, as the patient populations are not identical and the 
definition of triple-negative breast cancer or basal-like breast cancer differs across studies. 
Additionally, subset analyses with non-centralized review of tumor markers should be 
interpreted with caution since a substantial percentage of patients may not have triple-
negative disease based on incorrect classification. Prospective trials with carefully defined 
triple-negative status using validated biomarker analysis are necessary to optimize the 
use of targeted therapy in this patient population. 
2.6 Molecular profiling in prognosis and patient selection for neoadjuvant systemic 
therapy 
Gene expression profiling with the use of DNA microarrays has added valuable information 
to our understanding of breast cancer biology. In the seminal work of Perou et al. (2011) the 
ability to interrogate thousands of genes at the same time was translated into a "molecular 
portrait" of each tumor sample studied, and the concomitant analysis of the individual 
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molecular portraits of breast cancer tumor samples made the definition of molecular 
subtypes of breast cancer possible (Perou et al., 2011). In order to analyze this large quantity 
of information (thousands of genes per sample evaluated), a hierarchical clustering method 
was used to group genes according to similar patterns of expression. The proposed 
molecular classification of breast cancer was divided into five classes: luminal-A, luminal-B, 
basal-like, HER2-positive and normal-like tumors (Sotiriou et al., 2003; Sorlie et al., 2003). 
Subsequently, the correlation between molecular subtypes and clinical data have shown a 
significant difference in overall survival between the subtypes. 
Despite this progress, the clinical applicability of molecular classification is limited by the tight 
correlation between the molecular subtypes and currently available immunohistochemical 
markers (ER, PR, HER2, Ki67) (Sotiriou & Pusztai, 2009). For example, the molecular subtype 
HER2-positive is clinically detected by IHC or fluorescent in situ hybridization (FISH) 
according to published guidelines (Sauter et al., 2009). Although a good correlation has been 
established between the molecular subtype HER2 and clinically assessed HER2-positive 
breast cancer, the opposite is not true, because 30% of HER2-positive breast cancers are 
molecularly characterized as luminal-B (Cheang et al., 2009). Luminal-A and luminal-B 
molecular subtypes are, by definition, hormone receptor positive tumors, but the distinction 
between these two subtypes is controversial. 
One of the proposed clinical definitions characterizes luminal-A and luminal-B tumors 
using hormone receptor status, HER2 status and the Ki67 index (percentage of Ki67-positive 
nuclei by IHC). Luminal-A is defined as being ER- and/or PR-positive, HER2-negative and 
Ki67-low (Ki67 index < 14%). Luminal-B is defined as ER- and/or PR- positive, HER2-
negative and Ki67-high (Ki67 index > 14%). Another luminal-B subtype has also been 
proposed, namely luminal HER2 enriched, with tumors being ER- and/or PR- positive, 
HER2-positive and Ki67-high (ki67 index > 14%) (Perou, 2011).  
Study Jinno et al (2011) was to evaluate the clinical utility of breast cancer intrinsic subtypes 
in the prediction of pathological complete response (pCR) in a cohort of breast cancer 
patients receiving neoadjuvant chemotherapy. 
Patients with stage II/III breast cancer received 4 cycles of chemotherapy XT (capecitabine 
1650mg/m2 on days 1-14 and docetaxel 60mg/m on day 8 every 3 weeks), followed by 4 
cycles of FEC (fluorouracil 500 mg/m2, epirubicin 90mg/m2, cyclophosphamide 
500mg/m2). Immunohistochemical (IHC) analysis of ER, PgR, HER2. EGFR, cito-ceratine 
5/6. and Ki67 was performed in core needle biopsy samples at baseline. Tumors were 
classified as luminal A (ER+ and/or PgR+, and Ki67<20%), Luminal В (ER+ and PgR+, and 
Ki67 > 20%). Luminal-HER2 (ER+ and/or PgR+, and HER2+), HER2-enriched (ER- PgR-, 
and HER2+), or triple-negative (ER-, PgR-, and HER2-). Triple-negative tumors with and 
without EGFR+ and/or cito-ceratine 5/6+ were further classified as basal-like and non-
basal-like TN (NBTN), respectively. Pathologic complete response (pCR) was defined as no 
microscopic evidence of residual viable tumor cells, invasive or noninvasive, in all resected 
specimens of the breast. Twenty-six (31.3%) patients were classified as luminal A, 12 (14.5%) 
were luminal B, 15 (18.1%) were luminal-HER2, 9 (10.8%) were HER2, 10 (12.0%) were basal-
like, and 11 (13.3%) were NBTN. The overall response rate was 90.4%, including a complete 
response in 30 patients and a partial response in 45 patients. The overall pCR rate was 15.5% 
(12/83). The highest pCR rate (40.0%) was observed in patients with basal- like tumors. In 
triple-negative patients, basal-like patients showed significantly higher pCR rate than NBTN 
patients (40.0% vs. 9.1%. p = 0.01). There were no cases with pCR in a cohort of luminal-
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HER2 subtype patients. A higher proportion of luminal В patients had pCR than luminal A 
patients (25.0% vs. 3.8%, p = 0.01). Data indicate that breast cancer subtypes are useful 
predictive biomarkers of pCR in breast cancer patients treated with neoadjuvant systemic 
chemotherapy. 
Despite advances, 20% to 30% of patients with early breast cancers will experience relapse 
with distant metastatic disease. Risk of recurrence is influenced by stage at initial 
presentation and the underlying biology of the tumor. Tumor size, nodal involvement, 
grade, lymphovascular invasion, and estrogen receptor (ER) and human epidermal growth 
factor receptor 2 (HER2) status are all independent risk factors for relapse (Chia et al., 2008). 
However, we do not have a comprehensive understanding of the patterns of spread and 
specific sites of recurrence. 
The objectives of the study by Kennecke et al. (2010) were to determine the influence of 
breast tumor molecular subtypes on site of metastatic disease and to define the associated 
patient outcomes using a large validated tissue microarray (TMA) of primary invasive 
breast cancer specimens. Ten-year survival estimates were significantly different (P 
<0.00l) among subgroups; 70% of patients with luminal A tumors were alive at 10 years 
compared with 54.4% of luminal B, 46.1% of luminal/ HER2, 48.1% of HER2-enriched, 
52.6% of basal-like, and 62.6% of nonbasal triple negative (TN) patients. Median duration 
of survival from time of first distant metastasis also differed significantly, with luminal A 
patients achieving the longest survival (2.2 years) followed by luminal В (1.6 years), 
luminal/HER2+ (1.3 years), HER2-enriched (0.7 years), basal- like (0.5 years), and triple-
negative (TN) nonbasal patients (0.9 years; P <0 .001). These differences in relapse 
according to subtype were maintained with 15-year distant relapse rates for luminal A 
(27.8%), luminal В (42.9%), luminal/HER2 (47.9%), HER2-enriched (51.4%), basal-like 
(43.1%) and TN nonbasal (35.1%) subgroups. 
The study by Kennecke et al. (2010) demonstrates important differences in metastatic 
behavior between the breast cancer subtypes as defined by a panel of immunohistochemical 
markers and contributes to an expanding knowledge of prognostic and predictive markers 
that will allow individualized therapy for advanced breast cancer similar to current 
approaches in development for early-stage disease. 
In the article by Voduc et al. (2010) a six-marker immunohistochemical panel (ER, PR, HER2, 
epidermal growth factor receptor, CK 5/6, and Ki-67) was used to classify nearly 3,000 
patients treated with breast conserving surgery (BCS) and radiation therapy (RT) or 
mastectomy as luminal-A, luminal-B, luminal-HER2, HER2-enriched, basal-like, and triple- 
negative nonbasal. The intrinsic molecular subtype was successfully determined in 2,985 
tumors. The median follow-up time was 12 years, and there have been a total of 325 local 
recurrences and 227 regional lymph node recurrences. Luminal A tumors (ER or PR 
positive, HER2 negative, Ki-67 < 14%) had the best prognosis and the lowest rate of local or 
regional relapse. For patients undergoing breast conservation, HER2-enriched and basal 
subtypes demonstrated an increased risk of regional recurrence, and this was statistically 
significant on multivariable analysis. After mastectomy, luminal B, luminal-HER2, HER2-
enriched, and basal subtypes were all associated with an increased risk of local and regional 
relapse on multivariable analysis. 
In a second important study assessing molecular profiling using an alternative classification 
scheme for risk assessment of locoregional relapse (LRR) in breast cancer, Mamounas et al. 
(2010) evaluated the 21-gene profile (Oncotype DX), in more than 1,500 patients with node-
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negative ER-positive disease from National Surgical Adjuvant Breast and Bowel Project 
studies treated by breast-conserving surgery (BCS) plus radiotherapy (RT) or mastectomy 
without RT. In the patients treated with mastectomy, a high recurrence score (RS) was 
associated with a significantly higher risk of local-regional recurrence (LRR). The results 
demonstrated that patients with node-negative ER- positive disease and a high 21 -gene 
recurrence score, particularly those patients younger than 50 years, had a relatively high 
risk of LRR with mastectomy without radiotherapy (RT), suggesting that the 21-gene 
profile test may identify a cohort of patients with lymph node-negative disease who may 
potentially benefit from postmastectomy RT. Given that this study was a retrospective 
analysis, it will be important to validate these data in another data set before changing 
standard treatment recommendations. In contrast, it appears that the low LRR rate in ER-
positive patients with a low 21-gene recurrence score is comparable to the low LRR rate in 
the luminal-A group identified in the Voduc et al. (2010) study and it is likely that a 
majority of these patients with low recurrence scores have tumors that would be 
categorized as luminal-A tumors. 
In addition to larger validation studies and companion molecular protocols linked to 
clinical trials evaluating molecular profiling in locoregional management of breast cancer, 
there is a need for additional basic research to identify molecular profiles that consistently 
predict for locally aggressive disease. It should be noted that both classification schemes 
(the 21-gene recurrence score and the luminal/HER2/basal scheme) are derived from 
years of research demonstrating the potential of these markers in risk assessment for 
metastasis and overall survival. While locoregional relapse and systemic metastasis are 
clearly linked, risk factors and potential molecular profiles, which best predict for 
locoregional relapse, may be quite different from those molecular profiles that predict for 
systemic metastasis. 
It appears from both the Voduc et al. (2010) study and the Mamounas et al. (2010) study that 
patients with favorable luminal-A tumors or those with a low 21-gene recurrence score are 
at low risk for both local relapse and systemic disease. Patients with basal-like tumors, 
which are clearly at high risk for systemic metastasis, may also have an increased risk for 
local-regional recurrence (LRR) after surgical and radiotherapy (RT) treatment. 
Although the proposed classification allows for broader application, due to the widespread 
use of IHC, some inherent limitations raise concern: IHC evaluation is limited by interobserver 
variability, qualitative readouts and technical reproducibility (Oyama et al., 2007).  
2.7 Prognostic utility of multigene assays 
The 21-gene recurrence score (RS) assay and 70-gene signature demonstrated prognostic utility 
in patients with both node-negative and node-positive early-stage, hormone receptor-positive 
breast cancer (Sotiriou & Pusztai, 2009). Neither assay has been validated nor demonstrated 
prognostic utility in hormone receptor-negative breast cancer. Both the 21-gene and 70-gene 
assays also provide additional information for treatment decision-making beyond algorithms 
based on standard clinicopathologic criteria such as Adjuvant-Online (Albain et al., 2009). 
Although the original validation of the 21-gene RS assay established its prognostic ability in 
patients treated with adjuvant tamoxifen, a recent study demonstrated similar prognostic 
ability in patients who received an aromatase inhibitor as upfront adjuvant therapy (Dowsett 
et al., 2008). For both prognosis and prediction, only the 21-gene RS assay has been studied 
with specimens from phase III adjuvant therapy trials (Albain et al., 2009, 2010). 
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The ability of Genomic Grade Index (GGI) to predict response to neoadjuvant chemotherapy 
was evaluated in 229 tumor samples collected before neoadjuvant chemotherapy with 
paclitaxel, fluorouracil, doxorubicin and cyclophosphamide (T/FAC) (Liedtke et al., 2009). 
In general, pathologic complete response (pCR) is associated with better disease outcome 
regardless of hormone receptor status (Guarneri et al., 2006). Histologic grade is known to 
be a predictor of pathologic complete response, but inherent limitations to histological grade 
assessment limits its applicability. 
In the evaluation of GGI as a predictor of response, a more precise method for evaluating 
pathologic response called residual cancer burden (RCB) was used as a comparator 
(Symmans & Peintiger, 2007). RCB better defines different ranges of pathologic response 
after neoadjuvant chemotherapy. It is calculated as continuous variable, using pathologic 
measurements of the primary tumor and nodal metastases. In post-treatment surgical 
resection specimens a bidimensional diameter of primary tumor bed and the proportion of 
invasive tumor cells in the same area are measured. The number of nodes containing 
metastases and the diameter of the large lymph node metastases are also components of 
RCB. The prognostic information obtained with RCB was evaluated in 382 patients treated 
with neoadjuvant chemotherapy. In a multivariate analysis containing age, clinical stage, 
hormone receptor status, hormone treatment and pathologic response (pCR versus residual 
disease), RCB was an important prognostic factor associated with distant relapse-free 
survival (HR = 2.50; 95% CI 1.70-3.69; p < 0.001). Minimal residual cancer burden (RCB-I) 
and pCR (RCB-0) were associated with similar favourable long-term relapse-free prognosis. 
RCB adds to a better understanding of response to primary chemotherapy. 
In the evaluation of GGI compared to RCB to predict chemotherapy response, a data set 
comprising 229 samples from 132 ER-positive and 97 ER-negative patients was used. All 
patients had HER2 non-amplified tumors, which avoided the interference of chemotherapy 
and trastuzumab response. Pathologic response was assessed as follows: RCB- 0 indicating 
pCR, and RCB-I, RCB-II, RCB-III for minimal, intermediate and extensive residual disease 
respectively. GGI was assessed for each tumor sample and assigned as low or high risk, as 
in the original publication, but also as a continuous variable. The GGI evaluation 
characterized 84.6% of grade 1 tumors as low risk and 88.3% of grade 3 as high risk. The 
histological grade 2 group was divided into 62.7% low risk and 37.3% high risk. For the ER-
positive and ER-negative subgroups, 44.8% and 89.6% respectively were assigned to the GGI 
high-risk category. For the overall group treated with neoadjuvant T/FAC, high-risk GGI 
was associated with higher response than low-risk GGI (40% versus 12%; p < 0.001). A 
positive correlation was observed between GGI high-risk category and the level of observed 
response to neoadjuvant chemotherapy, with 85.8% of patients with RCB-0 or RCB-I, 
characterized as GGI high-risk (Metzger et al., 2010). 
The similar outcome predictions between the different signatures motivated a search for 
underlying biologic processes that could be represented by different genes in non-
overlapping signatures. A large meta-analysis of publicly available breast cancer gene 
expression and clinical data evaluated the contribution of known biological processes to 
the performance of different gene signatures. "Coexpression modules" for ER signaling, 
ERBB2 amplification and proliferation were generated, putting together a comprehensive 
list of genes with highly correlated expression (Metzger et al., 2010). The meta-analysis 
was able to confirm in 2833 patients that the initial classification of breast cancer 
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molecular subtypes was highly conserved, with the exception of normal-like breast 
cancer, which could not be identified.  
In all breast cancer subtypes (HER2, basal-like, luminal-A, luminal-B) the coexpression 
module proliferation was the most important determinant of prognosis. Although the 
coexpression module HER2 could be identified in the subtype HER2, the prognostic 
information was mainly driven by genes related to proliferation. HER2 and basal-like 
subtypes were consistently characterized as high proliferative tumors. In the luminal 
subtypes, the module of genes related to proliferation could divide this group into a low-
proliferative subtype (A) with better prognosis and a highly proliferative group with poorer 
prognosis (B). The evaluation of clinical variables demonstrated that tumor size and nodal 
status still have independent prognostic value and need to be evaluated together with the 
information obtained from gene-signatures. 
Understanding breast cancer molecular heterogeneity has made it possible to develop 
gene signatures that can be applied to predict prognosis and response to therapies in daily 
practice. The superiority of gene signatures to classic histopathologic variables is related 
to their ability to better define a greater proportion of low-risk patients that do not need to 
be treated with systemic neoadjuvant and adjuvant therapy, while still correctly 
identifying those patients who fall into a high-risk group. Clinical variables related to the 
measurement of tumor progression such as tumor size and nodal involvement remain 
significantly associated with prognosis and should therefore continue to be evaluated in 
conjunction with gene signatures.  
3. Conclusion 
Neoadjuvant systemic therapy is an appropriate management strategy in certain well-
defined patient cohorts, namely those in whom surgery is not feasible due to locally 
advanced disease at presentation; patients with large tumors requiring mastectomy, but 
wishing for breast conservation; and patients participating in clinical trials. Neoadjuvant 
therapy does not improve the outcomes in terms of disease-free survival or overall survival 
(OS), compared with adjuvant systemic treatment, and should not be chosen with this 
intent. There is currently no evidence to support deviating from a planned neoadjuvant 
regimen by changing drugs based on the observed response. 
Advances in the understanding of breast cancer tumor biology have greatly increased the 
assessment of patient prognosis, as well as which patients most benefit from neoadjuvant 
chemotherapy or endocrine therapy. The current challenge is how to best merge multigene 
assays with clinical biologic variables to achieve classifiers with even greater predictive 
utility. The enhanced knowledge of breast cancer biologic heterogeneity has also led to the 
development and clinical investigation of novel therapeutics aimed at cell function and 
essential signaling pathways. These agents are already producing survival benefits in 
patients with early-stage or advanced disease. However, many questions remain regarding 
the appropriate use of these compounds, including optimal patient selection, preventing 
and overcoming resistance, and management of associated toxicities. Furthermore, there is 
increased attention to the need to block multiple targets simultaneously to optimize 
response and overcome resistance that results from signaling pathway cross-talk.  
Finally, multiple biomarkers of response have been evaluated and show promise, but are 
not yet ready for routine clinical use. 
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